|
1) Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Circulation. 2006; 114: e257-354
|
|
|
|
2) 児玉逸雄, 相澤義房, 井上 博, 他. 不整脈薬物治療に関するガイドライン. 日本循環器学会｢循環器病の診断と治療に関するガイドライン｣. Circ J. 2004; 68 Suppl IV: 981-1053
|
|
|
|
|
|
3) 小川 聡, 山下武志. J-Rhythm News No. 8 & 9. 東京: J-Rhythm・J-Rhythm II 試験事務局; 2007
|
|
|
|
|
|
4) Alboni P, Botto GL, Baldi N, et al. Outpatient treatment of recent-onset atrial fibrillation with the “pill-in-the-pocket" approach. N Engl J Med. 2004; 351: 2384-91
|
|
|
|
|
|
5) 井上 博. 発作性心房細動に対する抗不整脈薬単回(頓服)療法の位置づけ. 心電図. 2007; 27 Suppl 3: S-3-75-83
|
|
|
|
|
|
6) The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002; 347: 1825-33
|
|
|
|
|
|
7) Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002; 347: 1834-40
|
|
|
|
|
|
8) Testa L, Biondi-Zoccai GG, Dello Russo A, et al. Rate-control vs. rhythm-control in patients with atrial fibrillation: a meta-analysis. Eur Heart J. 2005; 26: 2000-6
|
|
|
|
|
|
9) Kumagai K, Nakashima H, Urata H, et al. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol. 2003; 41: 2197- 204
|
|
|
|
|
|
10) Vermes E, Tardif JC, Bourassa MG, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation. 2003; 107: 2926-31
|
|
|
|
|
|
11) Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005; 45: 712-9
|
|
|
|
|
|
12) Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. JACC. 2005; 45: 1832-9
|
|
|
|
|
|
13) Patti G, Chello M, Candura D, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation. 2006; 114: 1455-61
|
|
|
|
|
|
14) Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation. 2001; 104: 2886-91
|
|
|
|
|
|
15) Patel AA, White CM, Shah SA, et al. The relationship between statin use and atrial fibrillation. Curr Med Res Opin. 2007; 23: 1177-85
|
|
|
|
|
|
16) 篠原幸人, 吉本 高, 福内靖男, 他. 脳卒中一般の危険因子の管理: 心房細動—脳卒中治療ガイドライン2004. 脳卒中合同ガイドライン委員会(日本脳卒中学会/日本脳神経外科学会(脳卒中の外科学会)/日本神経学会/日本神経治療学会/日本リハビリテーション医学会)編集. 東京: 協和企画; 2004
|
|
|
|
|
|
17) Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999; 131: 492-501
|
|
|
|
|
|
18) Waldo AL, Becker RC, Tapson VF, et al. Hospi-talized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol. 2005; 46: 1729-36
|
|
|
|
|
|
19) ACTIVE Writing Group of the ACTIVE Investi-gators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006; 367: 1903-12
|
|
|
|
|
|
20) Haissaguerre M, Jais P, Shah DC, et al. Spon-taneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998; 339: 659-66
|
|
|
|
|
|
21) Pappone C, Rosanio S, Oreto G, et al. Circum-ferential radiofrequency ablation of pulmonary vein ostia: A new anatomic approach for curing atrial fibrillation. Circulation. 2000; 102: 2619- 28
|
|
|
|
|
|
22) Oral H, Scharf C, Chugh A, et al. Catheter ablation for paroxysmal atrial fibrillation: seg-mental pulmonary vein ostial ablation versus left atrial ablation. Circulation. 2003; 108: 2355-60
|
|
|
|
|
|
23) Nademanee K, McKenzie J, Kosar E, et al. A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate. J Am Coll Cardiol. 2004; 43: 2044-53
|
|
|
|
|
|
24) Oral H, Chugh A, Good E, et al. Radiofrequency catheter ablation of chronic atrial fibrillation guided by complex electrograms. Circulation. 2007; 115: 2606-12
|
|
|
|
|
|
25) Cappato R, Calkins H, Chen SA, et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation. 2005; 111: 1100-5
|
|
|
|
|
|
26) Oral H, Pappone C, Chugh A, et al. Circum-ferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med. 2006; 354: 934-41
|
|
|
|
|
|
27) Doshi RN, Daoud EG, Fellows C, et al. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol. 2005; 16: 1160-5
|
|
|
|
|
|
28) Carlson MD, Ip J, Messenger J, et al. A new pacemaker algorithm for the treatment of atrial fibrillation: results of the Atrial Dynamic Overdrive Pacing Trial (ADOPT). J Am Coll Cardiol. 2003; 42: 627-33
|
|
|
|
|
|
29) Doi A, Takagi M, Toda I, et al. Acute hemody-namic benefits of bi-atrial atrioventricular sequential pacing with the optimal atrioventricular delay. J Am Coll Cardiol. 2005; 46: 320-6
|
|
|
|
|